Astellas Pharma & Mass General Brigham Collaboration

Astellas Pharma Inc., a pharmaceutical company operating in more than 70 countries worldwide, announced a strategic partnership with Mass General Brigham, focused on translational medicine and early-stage development, to create an integrated approach to advancing the science and clinical experience.

The initial joint ventures will focus on critical areas of RandD investment for Astellas, including oncology, rare diseases and cell and gene therapy.

Astellas and Mass General Brigham’s collaboration goals are to accelerate innovation and explore and expand new research areas through collaborative research. We translate groundbreaking research into clinical trials and practical solutions that address critical unmet needs and aim to improve health for all. We use scientific and clinical expertise to inform and accelerate the development of new treatments.

Knowledge collaboration is an integral part of Astellas' innovation strategy. This supports the company's ongoing efforts to improve scientific knowledge, better understand diseases and their manifestations optimize clinical trials and transform patient care. Mass General Brigham, located in Boston, Massachusetts, is one of the nation's leading academic medical centers. The health system conducts translational research in all areas, including oncology, rare diseases, and cellular and genetic medicine, through research programs and project centers, including the Institute for Gene and Cell Therapy. This collaboration will leverage Brigham's clinical and research expertise and capabilities, including clinical data and human models.

Chris Coburn, chief innovation officer at Mass General Brigham, said: "Industry partnerships are critical to bringing new treatments to market and the 'clinical stage.'" This partnership demonstrates our commitment to advancing research and innovation, supporting three critical areas of rapid clinical progress and high patient demand: oncology, rare diseases, and cell and gene therapies.